Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study
Catherine A Chappell, Kimberly K Scarsi, Brian J Kirby, Vithika Suri, Anuj Gaggar, Debra L Bogen, Ingrid S Macio, Leslie A Meyn, Katherine E Bunge, Elizabeth E Krans, Sharon L Hillier, Catherine A Chappell, Kimberly K Scarsi, Brian J Kirby, Vithika Suri, Anuj Gaggar, Debra L Bogen, Ingrid S Macio, Leslie A Meyn, Katherine E Bunge, Elizabeth E Krans, Sharon L Hillier
Abstract
Background: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy. Physiological changes in pregnancy alter the pharmacokinetics of some medications; thus, our aim was to compare the pharmacokinetic parameters of ledipasvir 90 mg plus sofosbuvir 400 mg during pregnancy with non-pregnant women.
Methods: This was an open-label, phase 1 study of pregnant women with genotype 1 HCV infection and their infants. A reference group of women who had participated in pharmacokinetic studies of ledipasvir-sofosbuvir during phase 2 and 3 trials was used. Participants were enrolled at Magee-Womens Hospital (Pittsburgh, PA, USA) between 23 and 24 weeks' gestation and had a 12-week course of oral ledipasvir-sofosbuvir (daily 90 mg ledipasvir plus 400 mg sofosbuvir). Three 12-h intensive pharmacokinetic visits were done at 25-26, 29-30, and 33-34 weeks' gestation and individual pharmacokinetics were summarised by geometric mean across the three visits. The primary outcome, analysed in all participants without suspected dosing errors, was the ledipasvir-sofosbuvir area under the concentration-time curve of the dosing interval (AUCtau) during pregnancy compared with the reference group by geometric mean ratio. This study is registered with ClinicalTrials.gov, NCT02683005.
Findings: From Oct 1, 2016, to Sept 30, 2018, 29 pregnant women were screened and nine (31%) were enrolled. Eight (89%) women were included in the primary analysis. Ledipasvir and sofosbuvir exposures were similar in the pregnant women versus the non-pregnant reference group (geometric mean ratio of AUCtau ledipasvir 89·3% [90% CI 68·7-116·1]; sofosbuvir 91·1% [78·0-106·3]).
Interpretation: Ledipasvir-sofosbuvir was safe and effective without clinically meaningful differences in drug exposure among pregnant versus non-pregnant women.
Funding: National Institutes of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institutes of Health/Office of Research on Women's Health, and Gilead Sciences.
Conflict of interest statement
Declaration of interests CAC, DLB, ISM, and EEK are receiving research funding from Gilead Sciences and CAC has served as a consultant for Gilead Sciences, outside of the submitted work. EEK and CAC are receiving research funding from Merck and SLH has served as a consultant for Merck, outside of the submitted work. BJK, VS, and AG are employed by Gilead Sciences. All other authors declare no competing interests.
Figures
![Figure 1:. Mean concentration–time curves at each…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7491553/bin/nihms-1619162-f0001.jpg)
![Figure 2:. Ledipasvir and sofosbuvir plasma protein…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7491553/bin/nihms-1619162-f0002.jpg)
![Figure 3:. HCV viral response to ledipasvir–sofosbuvir…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7491553/bin/nihms-1619162-f0003.jpg)
References
- WHO. Global hepatitis report, 2017. (accessed March 1, 2020).
- Morse A, Barritt SA 4th, Jhaveri R. Individual state hepatitis C data supports expanding screening beyond baby boomers to all adults. Gastroenterology 2018; 154: 1850–51.
- Patrick SW, Bauer AM, Warren MD, Jones TF, Wester C. Hepatitis C virus infection among women giving birth—Tennessee and United States, 2009–2014. MMWR Morb Mortal Wkly Rep 2017; 66: 470–73.
- Ko JY, Haight SC, Schillie SF, Bohm MK, Dietz PM. National trends in hepatitis C infection by opioid use disorder status among pregnant women at delivery hospitalization—United States, 2000–2015. MMWR Morb Mortal Wkly Rep 2019; 68: 833–38.
- Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep 2015; 64: 453–58.
- Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59: 765–73.
- Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol 2017; 217: B2–12.
- American College of Obstetricians and Gynecologists. ACOG practice bulletin No 86: viral hepatitis in pregnancy. Obstet Gynecol 2007; 110: 941–56.
- Krans EE, Zickmund SL, Rustgi VK, Park SY, Dunn SL, Schwarz EB. Screening and evaluation of hepatitis C virus infection in pregnant women on opioid maintenance therapy: a retrospective cohort study. Subst Abus 2016; 37: 88–95.
- Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889–98.
- Lyerly AD. Dolutegravir: advancing ethical research in pregnancy. Lancet 2019; 394: 1972–74.
- Gilead Sciences. Harvoni package insert. March, 2015. (accessed June 3, 2020).
- German P, Mathias A, Brainard D, Kearney BP. Clinical pharmacokinetics and pharmacodynamics of ledipasvir/sofosbuvir, a fixed-dose combination tablet for the treatment of hepatitis C. Clin Pharmacokinet 2016; 55: 1337–51.
- Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 2015; 54: 677–90.
- Gilbert EM, Darin KM, Scarsi KK, McLaughlin MM. Antiretroviral pharmacokinetics in pregnant women. Pharmacotherapy 2015; 35: 838–55.
- Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879–88.
- German P, Moorehead L, Pang P, Vimal M, Mathias A. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. J Clin Pharmacol 2014; 54: 1290–98.
- Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677–84.
- US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, version 2.0. 2014. (accessed Feb 21, 2017).
- Chang J, Streitman D. Physiologic adaptations to pregnancy. Neurol Clin 2012; 30: 781–89.
- Mok J, Pembrey L, Tovo PA, Newell ML. When does mother to child transmission of hepatitis C virus occur? Arch Dis Child Fetal Neonatal Ed 2005; 90: F156–60.
- El-Sayed MH, Elakel W, Elsharkawy A, et al. DAA therapy in women of child bearing age: accidental conception during therapy and pregnancy outcome. The International Liver Congress 2019; Vienna, Austria; April 11, 2019. (abstr THU-137).
- Chappell CA, Hillier SL, Crowe D, Meyn LA, Bogen DL, Krans EE. Hepatitis C virus screening among children exposed during pregnancy. Pediatrics 2018; 141: e20173273.
- Kuncio DE, Newbern EC, Johnson CC, Viner KM. Failure to test and identify perinatally infected children born to hepatitis C virus-infected women. Clin Infect Dis 2016; 62: 980–85.
- Nydegger A, Srivastava A, Wake M, Smith AL, Hardikar W. Health-w. J Gastroenterol Hepatol 2008; 23: 226–30.
- Rodrigue JR, Balistreri W, Haber B, et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr 2009; 48: 341–47.
- Jarlenski MP, Krans EE, Kim JY, et al. Five-year outcomes among Medicaid-enrolled children with in utero opioid exposure. Health Aff 2020; 39: 247–55.
- Jhaveri R, Broder T, Bhattacharya D, Peters MG, Kim AY, Jonas MM. Universal screening of pregnant women for hepatitis C: the time is now. Clin Infect Dis 2018; 67: 1493–97.
- Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults—United States, 2020. MMWR Recomm Rep 2020; 69: 1–17.
- US Preventive Services Task Force. Hepatitis C virus infection in adolescents and adults: screening. (accessed April 13, 2020).
Source: PubMed